Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05723276
Other study ID # TBC
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 2024
Est. completion date January 2026

Study information

Verified date February 2023
Source King's College London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to learn about the brain network response in people who have functional neurological disorder who are administered with a single dose of the psychedelic psilocybin with therapeutic support. The main question it aims to answer is: Can the default mode network, a brain network thought to be relevent in FND, be modified by the administration of psilocybin based on functional magnetic resonance imaging before and after the dose?


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date January 2026
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria: 1. Age 25 - 60 years. 2. Fluent in the English language 3. A diagnosis of FND from a neurologist and/or neuropsychiatrist as per DSM-5 criteria 4. Moderate or severe symptoms (=4 on Clinical Global Impression Severity (CGI-S) scale) which have been present for >12 months and have failed to respond to best available treatment. 5. Able to tolerate fMRI scanning procedures. Failed to respond is defined as an inadequate response to a full course of FND-specific therapy, including psychological therapy (cognitive behavioural therapy) or physiotherapy. Either therapy must have been undertaken by a suitably trained expert in FND and must have been specifically targeted at FND symptoms. Exclusion Criteria: 1. Diagnosis of severe depression (defined as meeting DSM-5 criteria) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist. 2. Diagnosis of bipolar affective disorder (defined as meeting DSM-5 criteria for bipolar I or bipolar II) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist. 3. Diagnosis of a psychotic disorder (defined as meeting DSM-5 criteria) on the MINI 7.0, EXCEPT substance/medication induced psychotic disorder where the duration was limited to the acute period of direct intoxication with the substance/medication. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist. 4. Diagnosis of drug or alcohol dependence disorder (defined as meeting DSM-5 criteria) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist. 5. Diagnosis of a personality disorder (defined as meeting DSM-5 criteria) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist. 6. Diagnosis of any dementia (defined as meeting DSM-5 criteria for any dementia disorder) based on clinical interview by a psychiatrist. 7. Diagnosis of any autistic spectrum disorder (defined as meeting DSM-5 criteria for any dementia disorder) based on clinical interview by a psychiatrist. 8. Diagnosis of any learning disability (defined as meeting DSM-5 criteria for any dementia disorder) based on clinical interview by a psychiatrist 9. Significant suicidal behaviour in past 12-months defined using the Columbia-Suicide Severity Rating Scale (C-SSRS) and confirmation based on clinical interview by a psychiatrist 10. Any other factor which would render the participant unsuitable for psilocybin and/or interfere with a supportive therapeutic relationship and/or preclude safe follow-up. 11. Those unable to give informed consent 12. Medical diagnosis incompatible with psilocybin treatment (see Section 8.2.1) 13. Inability to provide a screening blood sample, urine sample or electrocardiogram. 14. Biochemical abnormalities (defined as falling outside the normal reference range) as evaluated by a full blood count, full biochemistry profile and thyroid function tests. Biochemical abnormalities must also be determined as clinically significant by a medical doctor to fulfil the criterion for exclusion. 15. Electrocardiographic abnormalities, defined as any abnormality that is not normal sinus rhythm and determined as clinically significant by a medical doctor. 16. Women of childbearing potential not using contraception. 17. Pregnant or breast-feeding women. 18. Non-registration with a GP or failure to consent to sharing of the GP summary care record and any psychiatric assessments held. 19. Those enrolled in another clinical or research study. 20. Use of any psychedelic substances >2 times in past 12 months. 21. Any factor which would exclude the participant from magnetic resonance imaging (e.g., presence of metal)

Study Design


Intervention

Drug:
Psilocybin
Psilocybin 25mg PO

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
King's College London

Outcome

Type Measure Description Time frame Safety issue
Primary Change in functional connectivity in default mode network One week prior dosing versus one week post dosing (intra-subject)
See also
  Status Clinical Trial Phase
Recruiting NCT04310670 - Integrated Treatment in FND (Functional Neurological Disorders) N/A
Not yet recruiting NCT06346873 - Demonstrating Efficacy of JOGO for the Treatment of Tremor N/A
Active, not recruiting NCT05941702 - Body Signal Integration Training: A Case Series N/A
Recruiting NCT06084325 - The Role of Oxytocin and Interoception in Functional Neurological Disorder
Active, not recruiting NCT05581810 - Rehabilitation for Functional Memory Symptoms After Concussion N/A
Completed NCT03325374 - BLB Study Back or Leg Pain and Bladder Symptoms Study
Recruiting NCT06149728 - Pain Assessment and Transcranial Magnetic Stimulation Tolerability in Patients With a Functional Neurological Disorder
Terminated NCT02764476 - Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder N/A
Not yet recruiting NCT06362161 - Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND
Active, not recruiting NCT03857347 - Psychoeducation Group Intervention for FND N/A
Terminated NCT03731078 - Pilot Study of Cognitive Behavioral Therapy-Informed Physical Therapy Intervention in Functional Neurological Disorders
Not yet recruiting NCT05731648 - Role of Functional Neurosurgery in Management of Spasticity
Not yet recruiting NCT06422819 - Clinical Evaluation of HRV Biofeedback in Functional Neurological Disorders Compared to Placebo N/A
Completed NCT05634486 - Efficacy of the Multidisciplinary Treatment to the Quality of Life of With Functional Movement Disorders N/A
Recruiting NCT06257069 - Tremor Retrainer Software Application for Functional Tremor N/A
Completed NCT04942600 - Behavioural and Electrophysiological Effects of rTMS in Functional Neurological Disorders N/A
Recruiting NCT06105996 - ADIE-FS - Aligning Dimensions of Interoceptive Experience in Patients With Functional Seizures N/A